<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01738893</url>
  </required_header>
  <id_info>
    <org_study_id>116850</org_study_id>
    <nct_id>NCT01738893</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of 300 mg Gabapentin</brief_title>
  <official_title>Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to confirm if two formulations of gabapentin (capsules) are&#xD;
      bioequivalent.&#xD;
&#xD;
      Test product was Darbetin® 300 mg (Laboratorios Dermatológicos Darier) and reference product&#xD;
      Nerotin® 300 mg (Pfizer). One capsule was the single dosage.&#xD;
&#xD;
      The study was prospective, open-label, randomized, crossover, single dose, with 02&#xD;
      treatments, 02 sequences and 02 periods, under fasting conditions.&#xD;
&#xD;
      The population was composed of 26 healthy volunteers, both genders, adults between 18-55&#xD;
      years.&#xD;
&#xD;
      The comparative bioavailability of the two formulations was evaluated based in statistical&#xD;
      comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations&#xD;
      in blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2011</start_date>
  <completion_date type="Actual">January 22, 2011</completion_date>
  <primary_completion_date type="Actual">January 22, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (CMAX) of drug gabapentin</measure>
    <time_frame>0.0, 0.50, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, and 24.0 postdosage</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of gabapentin</measure>
    <time_frame>0.0, 0.50, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, and 24.0 postdosage</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>A (test)/ B (reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of test and cross-over to reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (reference/ A (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of reference and cross-over to test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 300 mg</intervention_name>
    <description>Test product</description>
    <arm_group_label>A (test)/ B (reference)</arm_group_label>
    <arm_group_label>B (reference/ A (test)</arm_group_label>
    <other_name>Darbetin®</other_name>
    <other_name>Laboratorios Dermatologicos Darier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 300 mg</intervention_name>
    <description>Reference product</description>
    <arm_group_label>A (test)/ B (reference)</arm_group_label>
    <arm_group_label>B (reference/ A (test)</arm_group_label>
    <other_name>Nerotin®</other_name>
    <other_name>Pfizer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Males 18-55 years. Healthy based on comprehensive medical history, lab tests, Chest x-ray,&#xD;
        Electrocardiogram, negative tests for Hepatitis B and C, and HIV. Negative urine doping&#xD;
        test. BMI 19-26.5 kg/m2. Lab test in normal range +/- 10%. Blood pressure 139-90/89-50,&#xD;
        heart rate 100-55, respiratory rate 24-17, temperature 37.5-35 °C. Non-smoking at least for&#xD;
        10 hrs before study. Written informed consent. Women must be not pregnant, nor&#xD;
        breast-feeding.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Hypersensitivity to study medication or other related drug. History of cardiovascular,&#xD;
        renal, hepatic, metabolic, gastrointestinal, neurologic, endocrine, hematopoietic,&#xD;
        psychiatric or organic condition.&#xD;
&#xD;
        Requiring any drug interfering with minocycline pharmacokinetics. Exposed to inducers or&#xD;
        inhibitors of hepatic enzymes. Intake of possible toxic drugs 30 days before study. Intake&#xD;
        of any drug 14 days or 7 half-lives before study. Hospitalization or severe disease 60 days&#xD;
        before study. Receiving investigational drug out of study center 30 days before study.&#xD;
        Blood loss or blood donation =&gt;450 ml 60 days before study. Recent history of drug abuse&#xD;
        including alcohol. Intake of xanthine containing products 10 hrs before study. Intake of&#xD;
        grapefruit juice or hot-spice 10 hrs before study.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gabapentin</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mexico</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

